Hepatitis C virus is a major cause of chronic hepatitis and is responsible for majority of liver transplantation worldwide. It has got no vaccine for prevention. Interferon containing regimen was the only management options for treatment of Hepatitis C virus till last year. Due to side effect profile and treatment cost this treatment options was not reachable for general population. Besides, response rate was not so satisfactory (Genotype 1, 40-50%, Genotype 2 & 3, 70-80%). New oral antivirals were introduced in 2014 which has got little side effect profile as well as good treatment response rate (80-95%). These new drugs with their different combination regimens along with indications, contraindications and treatment monitoring of Hepatitis C virus are discussed briefly in this review.
Hepatitis C Virus (HCV) infection is one of the main cause of chronic liver disease worldwide. It infects 170 million people worldwide and 1.6% of the population of the United States 1 . HCV prevalence in Europe is 1.03%, Africa 5.3%, Mediterranian region 4.6%, Western pacific region 3.9% and South east Asia 2,13% 2 . In Bangladesh prevalence is 1% among health care workers 3 . About 55% to 85% of acutely infected persons ultimately lead to chronic infection 4 . Chronic HCV infection can lead to cirrhosis and hepatocellular carcinoma & Chronic HCV is the only chronic viral infection that can be cured by antiviral therapy 4 . Till recently, interferon (INF) and Ribavirin (RBV) was the treatment options for HCV with a sustained virologic response (SVR) rate of 40% to 50% for genotype 1 and 70% to 80% for genotype 2 and 3 infection 4 . In 2011, two protease inhibitor (direct acting antiviral) Telapravir and Bocepravir were licensed for Genotype 1 infection in combination with INF & RBV with a SVR rate 65-75% but due to side effect profile and cost they didn't became so popular 5 . In 2014, Sofosbuvir, Simepravir, Daclastavir was introduced with a SVR rate 80-95% with different combination & genotype 5 . In addition, Ledipasvir, Paritaprevir, Ombitasvir, Ritonavir & Dasabuvir has got excellent activity against HCV infection with a high SVR rate in various combinations. So, now HCV infection can be confidently treated with various INF free regimens also & obviously new era has been started in the treatment of HCV infection. Intent of this review is to simplify various treatment modalities of HCV for easy understanding of our physician to deal with HCV infection.
Management of HCV infection:

Goals and endpoints of HCV therapy:
The goal of therapy is to cure HCV infection in order to prevent hepatic cirrhosis, decompensation of cirrhosis, HCC, severe extra-hepatic manifestations and death.
The endpoint of therapy is an SVR, defined by undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after the end of therapy, as assessed by a sensitive molecular method with a lower limit of detection < _ 15 IU/ml. Both SVR12 and SVR24 have been accepted as endpoints of therapy by regulators in the US and Europe. Long-term follow-up studies have shown that an SVR corresponds to a definitive cure of HCV infection in more than 99% of cases. In patients with advanced fibrosis and cirrhosis, HCV eradication reduces the rate of decompensation and will reduce, albeit not abolish the risk of HCC. In these patients surveillance for HCC should be continued. In patients with decompensated cirrhosis, HCV eradication reduces the need for liver transplantation. Whether HCV eradication impacts mid-to long-term survival in these patients is unknown.
Pre-therapeutic assessment:
The causal relationship between HCV infection and liver disease should be established, liver disease severity must be assessed, and baseline virological parameters should be determined. Search for other causes of chronic liver disease, or factors which are likely to affect the natural history or progression of liver disease, should be systematically investigated and all patients should be tested for other hepatotropic viruses, particularly hepatitis B virus (HBV), and for human immunodeficiency virus (HIV). Possible comorbidities, including alcoholism, autoimmunity, genetic or metabolic liver diseases (for instance genetic hemochromatosis, diabetes or obesity) and the possibility of drug-induced hepatotoxicity should be assessed.
Assessment of liver disease severity
Assessment of liver disease severity is recommended prior to therapy. Identifying patients with cirrhosis or advanced (bridging) fibrosis is of particular importance, as the post-treatment prognosis depends on the stage of fibrosis. Assessment of the stage of fibrosis is not required in patients with clinical evidence of cirrhosis. Patients with cirrhosis need surveillance for HCC. Since significant fibrosis may be present in patients with repeatedly normal ALT, evaluation of disease severity should be performed regardless of ALT levels. Fibrosis stage can be assessed by non-invasive methods initially, with liver biopsy reserved for cases where there is uncertainty or potential additional aetiologies.
HCV RNA detection/quantification and genotype determination
HCV RNA detection/quantification is indicated for the patient who may undergo antiviral treatment. HCV RNA quantification should be made by a reliable sensitive assay with a lower limit of detection of < _ 15 IU/ml, and HCV RNA levels should be expressed in IU/ml. The HCV genotype, including genotype 1 subtype, should alsobe assessed prior to treatment initiation. Genotyping/subtyping should be performed with an assay that accurately discriminates subtype 1a from 1b. HCV resistance testing should not be performed prior to therapy, because the SVR rates are very high both in patients without and with detectable amounts of resistance-associated variants.
Indications for treatment: Who should be treated and when?:
Treatment is indicated * All treatment-naive and treatment-experienced patients with compensated and decompensated liver disease. 
Treatment is justified * Patients with moderate fibrosis (F2)
Treatment can be deferred * Patients with no or mild disease (F0-F1) and none of the above-mentioned extrahepatic manifestations.
Treatment is not recommended * Patients with limited life expectancy due to nonliver related co-morbidities.
Contra-indications to therapy:
IFN-α and Ribavirin
This regimen is absolutely contra-indicated in the following patient groups: uncontrolled depression, psychosis or epilepsy; pregnant women or couples unwilling to comply with adequate contraception; severe concurrent medical diseases and co-morbidities including retinal disease, autoimmune thyroid disease; decompensated liver disease. The use of PegIFN-α is not recommended in patients with absolute neutrophil counts <1500/mm 3 
Hepatocellular Carcinoma:
Although the long-term benefit of antiviral therapy to reduce the risk of HCC in patients undergoing resection or ablation for HCV-associated HCC is unknown, these patients frequently have advanced fibrosis and should receive appropriate antiviral therapy for their liver disease, following the guidelines above.
HBV co-infection:
1. Patients should be treated with the same regimens, following the same rules as HCV monoinfected patients.
2. If HBV replicates at significant levels before, during or after HCV clearance, concurrent HBV nucleoside/nucleotide analogue therapy is indicated.
Management of Acute HCV Infection:
Most patients with acute hepatitis C are asymptomatic, but a high rate of chronicity is expected without treatment (50-90%). Symptomatic disease with jaundice, female gender and young age has been associated with spontaneous viral clearance, but none of these parameters accurately predicts spontaneous resolution at the individual level. Patients with acute hepatitis C should be considered for antiviral therapy in order to prevent progression to chronic hepatitis C. The ideal time point for starting therapy has not been firmly established. Some investigators estimate that the onset of ALT elevation, with or without clinical symptoms, may be the ideal time point for treatment. It has also been suggested that patients should be followed with 4weekly HCV RNA quantification and that only those who remain HCV RNA positive at 12 weeks from onset should be treated.
5.
Assessment of other causes of liver disease is recommended for patients who develop persistently abnormal liver tests after achieving an SVR.
Follow up of untreated patient and of patient with treatment failure:
1. Should be regularly followed up. 2. Noninvasive methods of fibrosis staging (elastography) 1 to 2 yearly. 3. Surveillance for hepatocellular carcinoma with ultrasound testing every 6 months is recommended for patients with advanced fibrosis (ie, Metavir stage F3 or F4) or cirrhosis.
Endoscopic surveillance for esophageal varices is
recommended if cirrhosis is present. 5. Evaluation for retreatment is recommended as effective alternative treatments become available.
Conclusion:
With invent of new oral direct acting antiviral drugs for the management of HCV infection we are hopeful that our resource limited population can be treated effectively. Though all oral drugs are not available in our country (Only Ribavirin &Sofosbuvir are available), we can hope that in the near future more drug will be available to combat our HCV infected patient.
